AARD Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $321.2K.
Where they traded
Last open-market purchase: December 11, 2025 , by Lee Tien-Li .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sun Nelson | See Remarks | Sell 10b5-1 | 62,000 | $5.18 | $321.2K | 35,475 −63.6% of holding | |
| Sun Nelson | See Remarks | Sell 10b5-1 | 14,754 | $5.00 | $73.8K | 97,475 −13.1% of holding | |
| Lee Tien-Li | Chief Executive Officer | Buy | 7,000 | $14.48 | $101.4K | 1,551,613 | |
| Sun Nelson | Chief Financial Officer | Buy | 3,000 | $14.40 | $43.2K | 108,484 | |
| Lee Tien-Li 2 fills | Chief Executive Officer | Buy | 10,000 | $9.66 | $96.6K | 1,543,384 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.